G1 Therapeutics Inc. (GTHX) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCCP) Comparison side by side

Both G1 Therapeutics Inc. (NASDAQ:GTHX) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCCP) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
G1 Therapeutics Inc. 25 0.00 27.91M -2.97 0.00
Cyclacel Pharmaceuticals Inc. 5 0.00 12.05M -0.51 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for G1 Therapeutics Inc. and Cyclacel Pharmaceuticals Inc.

Profitability

Table 2 has G1 Therapeutics Inc. and Cyclacel Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
G1 Therapeutics Inc. 110,098,619.33% -34.3% -32.4%
Cyclacel Pharmaceuticals Inc. 236,274,509.80% 0% 0%

Analyst Recommendations

G1 Therapeutics Inc. and Cyclacel Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
G1 Therapeutics Inc. 0 0 1 3.00
Cyclacel Pharmaceuticals Inc. 0 0 0 0.00

G1 Therapeutics Inc.’s upside potential currently stands at 81.31% and an $45 average target price.

Insider & Institutional Ownership

Roughly 97.3% of G1 Therapeutics Inc. shares are owned by institutional investors while 0.69% of Cyclacel Pharmaceuticals Inc. are owned by institutional investors. About 17.81% of G1 Therapeutics Inc.’s share are owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
G1 Therapeutics Inc. 6.02% 0.17% -36.46% 23.05% -34.44% 19.58%
Cyclacel Pharmaceuticals Inc. -7.61% -2.34% -15% -32.38% -35.21% -32%

For the past year G1 Therapeutics Inc. has 19.58% stronger performance while Cyclacel Pharmaceuticals Inc. has -32% weaker performance.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.